SCM
RPRX icon

Stonepine Capital Management’s Royalty Pharma RPRX Stock Holding History

Stonepine Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-212,000
Closed -$6M – 55
2024
Q3 		$6M Buy
+212,000
New +$5.87M 3.79% 5

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stonepine Capital Management's RPRX Position: Q4 2024 in Review

Stonepine Capital Management sold out of Royalty Pharma (RPRX) in Q4 2024, closing a stake of 212,000 shares — an estimated $6M sold.

Stonepine Capital Management first reported a position in RPRX in Q3 2024 and held it in 1 quarter. The position peaked at $6M in Q3 2024. 416 funds tracked by Wall St. Rank hold RPRX as of Q4 2024.

  • Stonepine Capital Management reported no remaining Royalty Pharma position as of Q4 2024 after selling out during the quarter.
  • Stonepine Capital Management sold 212,000 Royalty Pharma shares in Q4 2024, an estimated $6M.
  • Stonepine Capital Management first reported a position in Royalty Pharma in Q3 2024 and held it in 1 quarter.
  • Stonepine Capital Management's Royalty Pharma position peaked at $6M in Q3 2024.
  • 416 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2024.

Based on Stonepine Capital Management's 13F filing for Q4 2024, filed 14 Feb 2025.